The one year significant infection rate (infections requiring medical intervention) after double umbilical cord blood transplant using a novel conditioning regimen of fludarabine/melphalan/low dose total body radiation. The data is shown as the number of significant infections participants experienced during the first year, measured from the start of treatment.

The two participants found to be ineligible after being consented and registered were excluded from the analysis.

The median number of days measured from the time of transplantation, until the first documented neutrophil engraftment. neutrophil engraftment is defined as the first of 3 consecutive days of absolute neutrophil count > 500 neutrophils per microliter of blood.

The two participants found to be ineligible after being consented and registered were excluded from the analysis. In addition to those two participants, the 8 participants that did not achieve engraftment were not included in the analysis.

The time to platelet engraftment is measured from the time of transplantation until the time of first documented platelet engraftment. Platelet engraftment is defined as a platelet count ≥ 20,000/µL for three consecutive measurements over three or more days. The first of the three days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 3 days or in the following 7 days after the day of engraftment, unless the platelet transfusion is being given specifically to achieve a platelet threshold to allow an elective invasive procedure, such as a central catheter removal.

The two participants found to be ineligible after being consented and registered were excluded from the analysis. In addition to those two participants, the 10 participants that did not achieve engraftment were not included in the analysis.

Primary graft failure is defined as the failure to achieve an absolute neutrophil count (ANC) >500/ µL by day 42, in the absence of relapse.

Acute GVHD is assessed using Consensus Criteria:

Organ Classifications:

• 0: No rash due to GVHD; Bilirubin < 2 mg/dL; < 500 mL diarrhea/ day
• 1: Maculopapular rash < 25% of body surface; Bilirubin 2-3 mg/dL; 500 to 999 mL diarrhea/ day or persistent nausea with histologic evidence of GVHD in stomach/ duodenum
• 2: Maculopapular rash 25-50% of body surface; Bilirubin 3.1-6 mg/dL; 1,000 to 1,499 mL diarrhea/ day
• 3: Maculopapular rash > 50% of body surface; Bilirubin 6.1-15 mg/dL; 1,500 or more mL diarrhea/ day
• 4: Generalized erythroderma with bullous formation; Bilirubin > 15 mg/dL; Severe abdominal pain with or without ileus

Overall Clinical Grade:

• 0: No Stage 1-4 of any organ
• I: Stage 1-2 rash and no liver or gut involvement
• II: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 gut involvement
• III: None to Stage 3 skin rash with Stage 2-3 liver involvement, or Stage 2-4 gut involvement
• IV: Stage 4 skin rash, or Stage 4 liver involvement

The two participants found to be ineligible after being consented and registered were excluded from the analysis.

Chronic Graft Versus Host Disease (GVHD) is assessed using the National Institutes of Health (NIH) consensus criteria.

The two participants found to be ineligible after being consented and registered were excluded from the analysis.

The percentage of treatment related participant deaths within 100 days of receiving umbilical cord blood transplantation. All deaths in the absence of relapse of the primary malignancy will be considered treatment related mortality.

The two participants found to be ineligible after being consented and registered were excluded from the analysis.

CD4 counts were only available for 11 participants at the 12 months time point

The percentage of participants that have not died or had disease progression by two years. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.

The two participants found to be ineligible after being consented and registered were excluded from the analysis.

The percentage of participants alive at two years

The two participants found to be ineligible after being consented and registered were excluded from the analysis.

The percentage of participants that relapsed within 12 months. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.

The number of participants that were found to have lymphoma post-transplant.